Cardiovascular Systems to Present PAD Data and Offer Educational Sessions at AMP Chicago 2013 Symposium
August 06 2013 - 11:32AM
Business Wire
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical
device company developing and commercializing innovative
interventional treatment systems for vascular disease, will present
data from its studies of peripheral arterial disease (PAD), as well
as offer educational sessions, at the upcoming AMP (Amputation
Prevention) Symposium in Chicago, August 8-10.
AMP Podium Presentations
CSI will present data about orbital atherectomy in the treatment
of PAD during the following podium presentations at AMP:
Thursday, Aug. 8
- 10:50 – 11 a.m., Dr. George L. Adams,
Rex Healthcare and University of North Carolina Health Systems,
Garner, N.C.: “Orbital Atherectomy ATK and BTK”
- 11 – 11:10 a.m., Dr. Jihad Mustapha,
Metro Heart & Vascular, Wyoming, Mich.: Taped case
presentation: “Orbital Atherectomy”
- 11:18 – 11:26 a.m., Dr. Raymond
Dattilo, St. Francis Health Center, Manhattan, Kan.: “Distal
Protection Devices: Are They Needed During Atherectomy Cases?”
Friday, Aug. 9
- 1:13 – 1:21 p.m., Dr. Jihad Mustapha:
Tibiopedal Arterial Minimally Invasive (TAMI) Retrograde
Revascularization – TAMI Technique
Saturday, Aug. 10
- 8:28 – 8:38 a.m., Dr. Raymond Dattilo:
“The Wrath of Calcification in CLI Patients: How Does It Impact
Diagnostic Modalities and Revascularization Options?”
- 11:34 – 11:40 a.m., Dr. George Adams:
“Orbital Atherectomy in 6 Minutes”
- 1:44 – 1:51 p.m., Dr. Raymond Dattilo:
“Is Calcium a Major Barrier for Drug Eluting Delivery and What Are
the Solutions to Improve Drug Delivery?”
AMP Poster Sessions
The following posters will be featured at AMP, Thursday, Aug. 8,
through Saturday, Aug. 10, from 7:30 a.m. to 6 p.m.:
- Dr. George L. Adams, Rex Healthcare,
Raleigh, NC: “Orbital Atherectomy Outcomes of the Claudicant
Patient Population within the CONFIRM Series”
- Dr. Tony Das, Cardiology and
Interventional Vascular Associates, Dallas, Texas: “Orbital
Atherectomy Outcomes of the Critical Limb Ischemia Patient
Population within the CONFIRM Series”
- Dr. Michael Lee, UCLA Medical Center,
Los Angeles, Calif.: “Pooled Analysis of the CONFIRM Registries:
Outcomes in Patients with Renal Disease Treated for Peripheral
Arterial Disease with Orbital Atherectomy” and “Pooled Analysis of
the CONFIRM Registries: Impact of Gender on Outcomes in Patients
Treated for Peripheral Arterial Disease with Orbital
Atherectomy”
Atherectomy
Workshop and Cadaver Summit: Aug. 8
WHAT: CSI has provided an
educational grant for a roundtable atherectomy workshop and cadaver
course at AMP, featuring ultrasound guided tibial and pedal access
followed by orbital atherectomy treatment.
WHEN:
Thursday, Aug. 8, 1 – 5 p.m.
WHERE:
Roundtable Atherectomy Workshop Grand Ballroom Chicago Marriott
Downtown – Magnificent Mile 540 N. Michigan Ave. Chicago, IL
Atherectomy Summit Cadaver Course
6th Floor Indiana, Iowa, Michigan and
Michigan State Rooms
Chicago Marriott Downtown – Magnificent Mile 540 N. Michigan Ave.
Chicago, IL
Lunch Symposium:
Aug. 8
WHAT: Leading PAD physicians will
share their expertise during a lunch symposium at AMP. The
symposium will cover the many costs of calcium and the usage of
orbital atherectomy for plaque modification, as well as successful
treatment case studies, and more.
WHEN:
Thursday, Aug. 8, 11:50 a.m. – 12:50 p.m.
WHERE:
Grand Ballroom Chicago Marriott Downtown – Magnificent Mile 540 N.
Michigan Ave. Chicago, IL
SCHEDULE:
The Many Costs of Calcium, Dr. Lawrence Garcia, St. Elizabeth’s
Medical Center, Boston, Mass. The Orbital Atherectomy
Revolution, Dr. Robert Vorhies, Cox Health Systems, Springfield,
Mo. The Orbital Evidence: Successful Orbital Atherectomy
Treatment Case Studies, Dr. Jihad Mustapha Q &
Atherectomy
CSI Booth at AMP: Aug. 9 –
10
Visit CSI at booth #409, 9:15 a.m. – 6:30 p.m. Friday, Aug. 9
and 9:30 a.m. – 3:30 p.m. Saturday, Aug. 10 to meet the company’s
calcium experts and learn more about CSI’s unique orbital
technology.
About Peripheral Arterial DiseaseAs many as 8 million to
12 million Americans, most over age 65, suffer from PAD, which is
caused by the accumulation of plaque in peripheral arteries
(commonly the pelvis or leg) reducing blood flow. Symptoms include
leg pain when walking or at rest. Left untreated, PAD can lead to
severe pain, immobility, non-healing wounds and eventually limb
amputation. With risk factors such as diabetes and obesity on the
rise, the prevalence of PAD is growing faster than the rest of the
population.
Millions of patients with PAD may benefit from treatment with
orbital atherectomy utilizing the Stealth 360° and Diamondback
360°, minimally invasive catheter systems developed and
manufactured by CSI. These systems use a diamond-coated crown,
attached to an orbiting shaft, which sands away plaque while
preserving healthy vessel tissue — a critical factor in preventing
reoccurrences. Balloon angioplasty and stents have significant
shortcomings in treating hard, calcified lesions. Stents are prone
to fractures and high recurrence rates, and treatment of hard,
calcified lesions often leads to vessel damage and suboptimal
results.
About Cardiovascular Systems, Inc.Cardiovascular Systems,
Inc., based in St. Paul, Minn., is a medical device company focused
on developing and commercializing innovative solutions for treating
vascular and coronary disease. The company’s Orbital Atherectomy
Systems treat calcified and fibrotic plaque in arterial vessels
throughout the leg in a few minutes of treatment time, and address
many of the limitations associated with existing surgical, catheter
and pharmacological treatment alternatives. The U.S. FDA granted
510(k) clearance for the use of the Diamondback Orbital Atherectomy
System in August 2007. To date, nearly 110,000 of CSI’s devices
have been sold to leading institutions across the United States.
CSI has also completed its ORBIT II Investigational Device
Exemption clinical trial to evaluate the safety and effectiveness
of its orbital technology in treating coronary arteries. The
coronary system is limited by federal law to investigational use
and is currently not commercially available in the United
States.
For more information, visit the company’s website at
www.csi360.com.
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From Sep 2023 to Sep 2024